BP 012 - Brillian Pharma
Alternative Names: BP-012 - Brillian PharmaLatest Information Update: 10 Mar 2024
At a glance
- Originator Brillian Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Leukaemia
Most Recent Events
- 24 Jan 2024 Clinical trials in Leukaemia (In children) (PO), prior to January 2024 (Brillian Pharma pipeline, January 2024)
- 24 Jan 2024 Brillian Pharma plans to launch BP 012 in Leukaemia in China in the third quarter of 2025 (Brillian Pharma pipeline, January 2024)
- 24 Jan 2024 Brillian Pharma plans to launch BP 012 in Leukaemia in USA in the third quarter of 2025 (Brillian Pharma pipeline, January 2024)